Los Angeles, California

SYMPOSIUM INFORMATION

>General Information
>Faculty
>Program/Schedule
>Accreditation
>Registration
>Hotel Reservations
>Privacy Policy

Supported by:
PIH Health Good Samaritan Hospital
Los Angeles, CA

Officially Endorsed by:
American College of Cardiology
California Chapter

FIFTH ANNUAL SYMPOSIUM
Contemporary Management of
Cardiovascular Disease in Women
April 23, 2022
Omni Los Angeles Hotel
Los Angeles California

PROGRAM / SCHEDULE

Saturday, April 23

6:45     Registration Opens

6:55-7:55     Breakfast

6:55-7:55
Product Theatre (Non-CME)
A treatment option for appropriate HFrEF patients following a
worsening HF event
    • Highlight the burden of HFH in patients with HFrEF.
    • Review a treatment option for reducing the risk of HFH and
       CV death in appropriate patients with HFrEF.

    Dr. Catherine Marti
    Piedmont Heart Institute - Athens, Georgia

    Supported by: Merck

Please Pre-Register for this Online Presentation by clicking on this link: > Register Once registered please use the link sent to your e-mail to access the program. If participants pre-register prior to the event they can avoid waiting for the link during the actual presentation.

8:05-8:10
Introductory Remarks

8:10-8:35
Cardiovascular Disease in Women: 2022 Update
    Christina Economides, MD, MM, FSCAI

8:35-9:00
Cardiovascular Consequences of COVID: Acute and Long-term
    Shira Shafir, PhD, MPH

9:00-9:25
Microvascular Disease: INOCA and MINOCA Update 2022
    Janet Wei, MD, FACC

9:25-9:50
Effect of Diabetes on Cardiovascular Outcomes in Women
    Karol Watson, MD, PhD

9:50-10:05
Question & Answer

10:05-10:20     Break

10:20-10:45
Current Management of Pulmonary Arterial Hypertension
    Shelley Shapiro, MD, PhD, FACC

10:45-11:10
Cardio-Obstetrics: The Management of Cardiovascular Complications in Pregnancy
    Priya Pillutla, MD

11:10-11:35
Update on Dyslipidemia Management in Women
    Margo B Minissian, PhD, ACNP, CLS, AACC, FAHA

11:35-12:00
Effect of Intermittent Fasting and Diet on Cardiovascular Outcomes
    Christina Craigo, MSN, ACNP, AACC

12:00-12:15
Question & Answer

12:30-1:30     Lunch
Product Theatre (Non-CME)
Addressing Elevated Risk For Thrombotic CV Events in
Patients Across the CAD Spectrum
    • Understand the risk factors that contribute to the elevated risk for thrombotic cardiovascular events pre- and post-myocardial infarction in patients across the coronary artery disease spectrum.
    • Differentiate oral P2Y12 inhibitors with respect to their clinical pharmacology and examine the select differences between oral antiplatelet therapies.
    • Describe the role of BRILINTA in reducing the risk of cardiovascular events in patients with acute coronary syndrome, history of myocardial infarction, and high-risk coronary artery disease without prior myocardial infarction.

    Warren Fegenbush, PharmD, BCPS

    Supported by: AstraZeneca Pharmaceuticals, LP

1:40-2:05
Atrial Fibrillation in Women
    Anil Bhandari, MD, FACC, FHRS

2:05-2:30
Heart Failure Management in Women: Current Landscape and Pharmacologic Management
    Joseph Rahman, MD

2:30-2:55
Heart Failure Management in Women: Current Cardiac Device Considerations
    Ravi Sureddi, MD

2:55-3:20
The Era of TAVR: What is the role of SAVR?
    Katrine Zhiroff, MD, FACC, FSCAI

3:20-3:35
Question & Answer

3:35-3:50     Break

3:50-4:15
Transcutaneous Mitral Valve Repair (TMVR):
Are There Gender Differences?
    Christina Economides, MD, MM, FSCAI

4:15-4:40
Pushing the Limits of Structural Heart Disease
    Steven Burstein, MD

4:40-5:20
Major Cardiovascular Trials of 2019/2020/2021
Case-Based Presentations
Moderators:
    Christina Economides, MD, MM, FSCAI
    Katrine Zhiroff, MD, FACC, FSCAI

5:20-5:25     Adjourn